How much weight can you lose in the first month on semaglutide?

The first month is spent at 0.25 mg, a dose chosen for tolerance rather than efficacy. Some appetite reduction is common; large weight loss in month one is not the expected pattern.

Why has my weight loss stalled on semaglutide?

Plateaus are common and have several ordinary explanations: you may still be mid-titration and not yet at a therapeutic dose, your energy requirement falls as you lose weight, or appetite suppression has partially adapted. A stall is a prompt to review with a prescriber, not automatically a reason to increase the dose.

Do you regain weight after stopping semaglutide?

Weight regain after stopping is the typical outcome reported in follow-up studies. The drug changes appetite while it is being taken; it does not permanently reset it.

Semaglutide Guide

Semaglutide for Weight Loss: What to Expect, Month by Month

8 MIN READ

By Peptide Prime Editorial· Last reviewed 1 August 2026

How much weight will I lose on semaglutide, and how fast?

On semaglutide, appetite suppression usually appears early, but meaningful weight loss lags well behind it because the starting dose is deliberately too low to be therapeutic. The Wegovy schedule takes roughly four months to reach the 2.4 mg maintenance dose, stepping up every four weeks. In the STEP 1 trial, 1,961 adults with overweight or obesity and without diabetes took 2.4 mg weekly alongside lifestyle intervention for 68 weeks and lost a mean of 14.9% of body weight, against 2.4% on placebo — a treatment difference of 12.4 percentage points. Results vary widely around that average, and the trial extension found weight was largely regained after the drug was withdrawn.

Key facts

Time to maintenance dose: ~16 weeks (Wegovy)
Trial mean weight loss: −14.9% (STEP 1, 68 weeks)
Placebo arm: −2.4%
Trial size: 1,961 adults, without diabetes
Titration interval: Every 4 weeks

The titration schedule is the timeline

Semaglutide is not dosed at its effective level on day one. The label steps the dose up every four weeks, and that ladder exists to let gastrointestinal side effects settle at each level before the next increase. Trying to skip steps is the single most reliable way to make the side effects intolerable.

For Wegovy that means 0.25 mg for weeks 1–4, 0.5 mg in month 2, 1.0 mg in month 3, 1.7 mg in month 4, and 1.7–2.4 mg as maintenance from month 5 onward. So the first four months are not a plateau or a failure — they are the protocol working as designed.

Wegovy titration schedule, as stated on the approved label.
Period	Weekly dose	What it is for
Weeks 1–4	0.25 mg	Tolerance building — not a therapeutic weight-loss dose
Month 2	0.5 mg	Continued titration
Month 3	1.0 mg	Continued titration
Month 4	1.7 mg	Approaching maintenance
Month 5 onward	1.7–2.4 mg	Maintenance (2.4 mg maximum)

What the trial data actually says

STEP 1 (2021) is the trial the "about 15%" figure comes from. It randomised 1,961 adults with a BMI of 30 or above — or 27 with a weight-related condition — and without diabetes, 2:1, to 2.4 mg semaglutide weekly or placebo, both with lifestyle intervention, for 68 weeks. Mean weight change was −14.9% on semaglutide versus −2.4% on placebo.

Two things about that number are routinely misread. First, it is a mean across a trial population and the spread around it is wide — a substantial minority lose considerably more, and a substantial minority lose little. Second, both arms received lifestyle intervention, so the honest read of the drug's contribution is the 12.4-percentage-point difference, not the headline 14.9%.

You will also see 15.2% quoted for STEP 1, including in older versions of this site's own comparison table. The published primary endpoint is −14.9%.

How it compares to the newer compounds

Semaglutide is no longer the most effective compound in this class by trial weight loss. Tirzepatide reported 20.9% in SURMOUNT-1, and investigational compounds report higher still. What semaglutide has that those do not is duration of real-world use and an approved indication.

CagriSema — 25.3% (REDEFINE 2, Phase 3)
Retatrutide — 24.2% (TRIUMPH-2, Phase 3)
Tirzepatide — 20.9% (SURMOUNT-1, FDA-approved)
Semaglutide — 14.9% (STEP 1, FDA-approved)

What happens when you stop

Semaglutide treats the physiology of appetite while it is present, and that physiology reverts when it is withdrawn. Weight regain after discontinuation is the expected outcome rather than a failure of the drug, and it is the reason the labelled use is chronic weight management rather than a course of treatment.

Frequently asked questions

Where this falls short

Trial averages are a poor predictor of any individual result, and this article cannot tell you what you personally will lose. Only the semaglutide figure here is cited to its primary publication; the comparator percentages come from this site's own comparison dataset and have not each been traced back to their source papers. They rank the compounds on headline weight loss alone, which ignores what usually decides the choice in practice — cost, insurance coverage, supply, side-effect tolerance, and whether the compound is approved at all, which most of the higher-performing ones are not. Trials also enrolled specific populations under supervision with lifestyle support, so their results do not transfer cleanly to unsupervised use.

Sources